文献速递胸部肿瘤放疗放疗物理与技术

药物抑制HIF-1α减轻临床前图像引导放疗所致放射性肺纤维化

Pharmacologic Inhibition of HIF-1α Attenuates Radiation-Induced Pulmonary Fibrosis in a Preclinical Image Guided Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-09-15

该临床前研究利用内皮细胞特异性Hif1a敲除小鼠及条件性肺癌小鼠模型,探讨内皮HIF-1α在放射性肺纤维化(RIPF)中的作用。结果显示放疗前短期敲除内皮HIF-1α或放疗后使用HIF-1α抑制剂2-甲氧基雌二醇(2-ME)均可抑制RIPF及内皮间质转化(EndMT),且2-ME联合消融性高剂量放疗可抑制肿瘤生长。

要点

  • 放疗前短期而非长期敲除内皮Hif1a可抑制RIPF进展并减少EndMT。
  • 放疗后给予2-ME可有效抑制RIPF和EndMT。
  • 2-ME联合消融性高剂量放疗抑制多灶及单发肿瘤生长并减少正常及肿瘤区EndMT。

核心结论

  • HIF-1α介导的EndMT负性调节剂如2-ME可能成为放疗中RIPF的有前景抑制剂。

研究设计与样本

  • 使用诱导性Cre-lox介导的内皮Hif1a敲除小鼠品系评估HIF-1α抑制对RIPF的作用。
  • 构建条件性tdTomato;K-RasG12D;p53 flox/flox小鼠以追踪表达tdTomato的肿瘤细胞,评估图像引导放疗(IGRT)后药物HIF-1α抑制剂对RIPF的效果。

主要发现

  • 放疗前不久内皮特异性HIF-1α敲除可抑制RIPF进展并减少EndMT,而放疗前长期敲除则不能。
  • 放疗后使用新型HIF-1α抑制剂2-甲氧基雌二醇(2-ME)可有效抑制RIPF和EndMT。
  • 在非小细胞肺癌原发小鼠模型IGRT中,2-ME联合消融性高剂量放疗有效抑制RIPF及多灶和单发肿瘤生长,同时减少正常及肿瘤区域的放疗诱导EndMT。

临床怎么用

  • 临床前证据提示放疗后使用2-ME等HIF-1α抑制剂可能减轻RIPF并协同抑制肿瘤生长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation-induced pulmonary fibrosis (RIPF) is a long-term side effect of thoracic radiation therapy. Hypoxia-induced vascular endothelial mesenchymal transition (EndMT) can occur during the development of RIPF. Here, we examined the direct contribution of endothelial HIF-1α (EC-HIF1α) on RIPF. METHODS AND MATERIALS: An inducible Cre-lox-mediated endothelial Hif1a deletion mouse line was used to evaluate the potential of HIF-1α inhibition to suppress RIPF. To evaluate the effects of a pharmacologic HIF-1α inhibitor on RIPF after image guided radiation therapy (IGRT) for spontaneous lung adenocarcinoma, we generated conditional tdTomato; K-RasG12D; and p53 flox/flox mice to facilitate tracking of tumor cells expressing tdTomato. RESULTS: We found that vascular endothelial-specific HIF-1α deletion shortly before radiation therapy inhibited the progression of RIPF along with reduced EndMT, whereas prolonged deletion of endothelial HIF-1α before irradiation did not. Moreover, we revealed that postirradiation treatment with the novel HIF-1α inhibitor, 2-methoxyestradiol (2-ME) could efficiently inhibit RIPF and EndMT. In addition, IGRT using primary mouse models of non-small cell lung cancer showed that combined treatment of 2-ME with ablative high-dose radiation therapy efficiently inhibited RIPF and the growth of both multifocal and single tumors, concomitantly reducing radiation-induced EndMT of normal as well as tumor regions. CONCLUSION: These results suggest that a negative regulator of HIF-1α-mediated EndMT, such as 2-ME, may serve as a promising inhibitor of RIPF in radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Nam JK, Kim AR, Choi SH, et al. Pharmacologic Inhibition of HIF-1α Attenuates Radiation-Induced Pulmonary Fibrosis in a Preclinical Image Guided Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020. PMID: 32942004. doi:10.1016/j.ijrobp.2020.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。